<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05054946</url>
  </required_header>
  <id_info>
    <org_study_id>17/056</org_study_id>
    <nct_id>NCT05054946</nct_id>
  </id_info>
  <brief_title>The Effect of Laparoscopic Surgery on Ovarian Reserve According to Cyst Types</brief_title>
  <official_title>The Effect of Laparoscopic Surgery on Ovarian Reserve According to Cyst Types</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ege University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ege University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of our study is to compare the effect of laparoscopic ovarian cystectomy on ovarian&#xD;
      reserve in terms of different cyst types.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants who will be treated surgically for ovarian cysts will be included in the study.&#xD;
      Anti-Mullerian Hormone (AMH) levels of the participants will be investigated before the&#xD;
      surgery and 6 months after the surgery. All surgeries will be performed under general&#xD;
      anesthesia laparoscopically. After histopathological evaluation, the participants will be&#xD;
      divided into three groups; Group 1: Endometrioma, Group 2: Mature cystic teratoma (Dermoid&#xD;
      cyst) and Group 3: Serous or mucinous cystadenoma.&#xD;
&#xD;
      A total of fifty-five women will be included in the study.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">October 1, 2021</start_date>
  <completion_date type="Anticipated">September 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in AMH Level</measure>
    <time_frame>6 months</time_frame>
    <description>AMH levels of the participants will be investigated before the surgery and 6 months after the surgery.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">55</enrollment>
  <condition>Ovarian Cysts</condition>
  <arm_group>
    <arm_group_label>Endometrioma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who will have endometrioma after histopathological evaluation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Mature cystic teratoma (dermoid cyst)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who will have mature cystic teratoma (dermoid cyst) after histopathological evaluation.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Serous or mucinous cystadenoma</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants who will have serous or mucinous cystadenoma after histopathological evaluation.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Laparoscopic cystectomy</intervention_name>
    <description>All surgeries will be performed under general anesthesia by laparoscopically.</description>
    <arm_group_label>Endometrioma</arm_group_label>
    <arm_group_label>Mature cystic teratoma (dermoid cyst)</arm_group_label>
    <arm_group_label>Serous or mucinous cystadenoma</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  no ovarian surgery before&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Endocrinological pathologies&#xD;
&#xD;
          -  Suspicion of malignancy in preoperative laboratory and ultrasonographic evaluations&#xD;
&#xD;
          -  Detection of malignancy in histopathological examination&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabahattin Anil Ari, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ege University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sabahattin Anil Ari, MD</last_name>
    <phone>+905547139994</phone>
    <email>s.anil.ari.md@gmail.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Cagdas Sahin, Assc. Prof.</last_name>
    <phone>+905324676106</phone>
    <email>cagdasdr@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Ege University Hospital</name>
      <address>
        <city>İzmir</city>
        <zip>35100</zip>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sabahattin A Arı, MD</last_name>
      <phone>+905547139994</phone>
      <email>s.anil.ari.md@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>September 19, 2021</study_first_submitted>
  <study_first_submitted_qc>September 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 23, 2021</study_first_posted>
  <last_update_submitted>November 11, 2021</last_update_submitted>
  <last_update_submitted_qc>November 11, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ege University</investigator_affiliation>
    <investigator_full_name>Sabahattin Anıl Arı</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>ovarian reserve</keyword>
  <keyword>anti-mullerian hormone</keyword>
  <keyword>ovarian cyst</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cysts</mesh_term>
    <mesh_term>Ovarian Cysts</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

